Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/25724
Title: The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort
Authors: Franklin, HD
Russell, LL
Peakman, G
Greaves, CV
Bocchetta, M
Nicholas, J
Poos, J
Convery, RS
Cash, DM
van Swieten, J
Jiskoot, L
Lebouvier, T
Leitão, MJ
Lladó, A
Lombardi, G
Loosli, S
Maruta, C
Mead, S
Meeter, L
Moreno, F
Sanchez-Valle, R
Borroni, B
Laforce, R
Masellis, M
Tartaglia, MC
Graff, C
Galimberti, D
Rowe, JB
Finger, E
Synofzik, M
Vandenberghe, R
de Mendonça, A
Tagliavini, F
Santana, I
Ducharme, S
Butler, C
Gerhard, A
Levin, J
Danek, A
Otto, M
Sorbi, S
Le Ber, I
Pasquier, F
Rohrer, JD
Genetic FTD Initiative, GENFI
Afonso, S
Almeida, MR
Anderl-Straub, S
Andersson, C
Antonell, A
Archetti, S
Arighi, A
Balasa, M
Barandiaran, M
Bargalló, N
Bartha, R
Bender, B
Benussi, A
Bertoux, M
Bertrand, A
Bessi, V
Black, S
Borrego-Ecija, S
Bras, J
Brice, A
Bruffaerts, R
Camuzat, A
Cañada, M
Cantoni, V
Caroppo, P
Castelo-Branco, M
Colliot, O
Cope, T
Deramecourt, V
de Arriba, M
Di Fede, G
Díez, A
Duro, D
Fenoglio, C
Ferrari, C
Ferreira, CB
Fox, N
Freedman, M
Fumagalli, G
Funkiewiez, A
Gabilondo, A
Gasparotti, R
Gauthier, S
Gazzina, S
Giaccone, G
Gorostidi, A
Greaves, C
Guerreiro, R
Heller, C
Hoegen, T
Indakoetxea, B
Jelic, V
Karnath, HO
Keren, R
Kuchcinski, G
Langheinrich, T
Keywords: frontotemporal dementia;familial;C9orf72;GRN;MAPT;RSMS;CDR® plus NACC FTLD;VBM
Issue Date: 12-Jul-2021
Publisher: BioMed Central (part of Springer Nature)
Citation: Franklin, H.D. et al (2021) 'The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort', Alzheimer's Research and Therapy, 13 (1), 127, pp. 1 - 12. doi: 10.1186/s13195-021-00865-w.
Abstract: Copyright © The Author(s). 2021. Background: Although social cognitive dysfunction is a major feature of frontotemporal dementia (FTD), it has been poorly studied in familial forms. A key goal of studies is to detect early cognitive impairment using validated measures in large patient cohorts. Methods: We used the Revised Self-Monitoring Scale (RSMS) as a measure of socioemotional sensitivity in 730 participants from the genetic FTD initiative (GENFI) observational study: 269 mutation-negative healthy controls, 193 C9orf72 expansion carriers, 193 GRN mutation carriers and 75 MAPT mutation carriers. All participants underwent the standardised GENFI clinical assessment including the ‘CDR® plus NACC FTLD’ scale and RSMS. The RSMS total score and its two subscores, socioemotional expressiveness (EX score) and modification of self-presentation (SP score) were measured. Volumetric T1-weighted magnetic resonance imaging was available from 377 mutation carriers for voxel-based morphometry (VBM) analysis. Results: The RSMS was decreased in symptomatic mutation carriers in all genetic groups but at a prodromal stage only in the C9orf72 (for the total score and both subscores) and GRN (for the modification of self-presentation subscore) groups. RSMS score correlated with disease severity in all groups. The VBM analysis implicated an overlapping network of regions including the orbitofrontal cortex, insula, temporal pole, medial temporal lobe and striatum. Conclusions: The RSMS indexes socioemotional impairment at an early stage of genetic FTD and may be a suitable outcome measure in forthcoming trials.
Description: Availability of data and materials: Data are available upon reasonable request. The raw data of this project are part of GENFI and are not publicly available in accordance with the ethical approval. Data can be accessed upon reasonable request to JDR (j.rohrer@ucl.ac.uk).
Supplementary Information: Additional file 1: Figure S1. RSMS EX scores in each genetic carrier group, stratified by Global CDR® plus NACC FTLD scores. Significant differences from controls and within each carrier group are starred. Differences between carrier groups are not shown. Figure S2. RSMS SP scores in each genetic carrier group, stratified by Global CDR® plus NACC FTLD scores. Significant differences from controls and within each carrier group are starred. Differences between carrier groups are not shown. Figure S3. Negative correlations between RSMS total and CDR® plus FTLD NACC SOB scores were observed across all mutation carrier groups: C9orf72 (r = -0.67, p < 0.001), GRN (r = -0.59, p < 0.001), MAPT (r = -0.53, p < 0.001). Each dot represents one mutation carrier. Table S1. RSMS total test scores (mean and SD) in healthy controls split by age group. Table S2. Cumulative frequency of RSMS total test scores in healthy controls. Table S3. Adjusted mean differences in RSMS EX scores between the genetic groups stratified by Global CDR® plus NACC FTLD scores with 95% bias-corrected confidence intervals (significant values in bold). Table S4. Adjusted mean differences in RSMS SP scores between the genetic groups stratified by Global CDR® plus NACC FTLD scores with 95% bias-corrected confidence intervals (significant values in bold). Table S5. Correlation of RSMS total test score with cognitive tests. Significant results are in bold. Table S6. Positive neuroanatomical correlates of grey matter volume with the RSMS total score in each genetic group. Available at: https://static-content.springer.com/esm/art%3A10.1186%2Fs13195-021-00865-w/MediaObjects/13195_2021_865_MOESM1_ESM.docx .
URI: https://bura.brunel.ac.uk/handle/2438/25724
DOI: https://doi.org/10.1186/s13195-021-00865-w
Other Identifiers: ORCID iD: Martina Bocchetta https://orcid.org/0000-0003-1814-5024
127
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdf1.45 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons